News

According to the FTC, the money will be used to compensate consumers the company allegedly lured with deceptive offers.

The study advances the understanding of the leading cause of visual impairment in adults.

Coherus plans to file a Biologics License Application for FYB203 later in 2023 in preparation for an anticipated 2025 launch.

The Genentech Award is intended to provide early-career underrepresented minority investigators with an opportunity to explore novel and innovative research project ideas.

The United States Department of Justice originally filed the lawsuit in December 2021 on behalf of an elderly quadriplegic patient, alleging that Tempe, Arizona-based Barnet Dulaney Perkins Eye Center was requiring patients with mobility disabilities to hire third-party medical transport and transfer assistance for outpatient surgical procedures. American Vision Partners was named as a codefendant.

Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.

Study results show evidence for augmentation, offering hope to patients.

Investigators found that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

In a conversation with David Hutton of Ophthalmology Times®, Ferhina S. Ali, MD, MPH, discussed the real world use of faricimab in the IRIS Registry during a presentation this week at Hawaiian Eye in Kauai Hawaii, focusing on the use of faricimab for the treatment of neovascular AMD and diabetic macular edema.

Timely access to effective diagnosis and cross-linking is key to positive outcomes

Until new innovations began transforming the field a decade ago, ophthalmologists had a limited toolbox. This option allows ophthalmologists to provide positive outcomes for their patients.

Terms for the deal for AcuFocus were not revealed by the companies.

The ARVO Foundation Collaborative Research Fellowship is intended to promote international scientific interactions and innovative research.

According to researchers, factors that were associated with all type of visual impairment included older age, lower education level, and lower income were associated with all types of visual impairment.

Diabetic retinopathy is the leading cause of blindness in American adults, and a team of researchers believes the source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.

Joshua Mali, MD, offers his prognostications for the new year

A collaborative team of researchers with Oregon Health & Science University and Oregon State University are using lipid nanoparticles to target light-sensitive cells in the eye.

According to the U.S. Attorney’s Office for the Northern District of Georgia, Aarti D. Pandya, MD, settled allegations that she performed and billed for medically unnecessary cataract surgeries and diagnostic tests.

A study was conducted with the goal of evaluating a correlation between the number of peer-reviewed publications published before a residency and the subsequent peer-reviewed publications or career choices of doctors who graduated from an Ophthalmology residency program.

The EyeMobile will visit approximately 250 preschools to provide vision services to low-income families.

Viridian Therapeutics unveils positive data from its ongoing Phase 1/2 trial evaluating low dose VRDN-001 in patients diagnosed with TED.

The study could lead to early diagnosis and treatment of age-related macular degeneration.

According to the company, gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride treatment administered via the company’s microdose formulation decreased inflammation from preserved glaucoma solutions compared to drops.

A study by researchers at Oregon Health & Science University, the University of Chicago, Harvard University and Johns Hopkins University reveals more churn in workforce and greater reliance on physician assistants.

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report.

The results from an exchange trial demonstrated a second administration of travoprost intraocular implant and removal of the original implant was safe and well-tolerated, while the company also provided updates for several of its corneal health pipeline programs for the treatment of keratoconus and dry eye disease.

With the safety and efficacy of phacoemulsification having increased to the point that it is no longer standard practice to examine patients the day after surgery, clinicians may be unfamiliar with the potential causes of reduced vision when presented with a patient in the immediate postoperative period.

According to the company, it will initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in the first quarter of 2023.